

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Boulanger, D. et al.

Serial No.: 10/523,836

Art Unit: Not yet assigned

Filed : February 7, 2005

Examiner: Not yet assigned

For : **USE OF NF-KAPPA B INHIBITORS FOR THE TREATMENT OF MASTITIS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

11-15-05

(Date of Deposit)

Ellen Ciambro Coletti

(Name of applicant, assignee, or Registered Representative)

(Signature)

11-15-05

(Date of Signature)

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**Response to Comply with Requirements for Patent Applications Containing
Nucleotide and/or Amino Acid Sequence Disclosures**

Dear Sir:

Pursuant to the requirements of 37 CFR 1.121(e), 1.821(f), 1.821(g), 1.825(b) and further to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, dated September 15, 2005, Applicants submit an initial Sequence Listing in computer readable form (CRF) and in written form for entry into the subject application.

I hereby verify that the contents of the Sequence Listing information recorded in computer readable form is identical to the written version of the Sequence Listing and does not introduce new matter into the patent application as filed.

Furthermore, a Verified Statement concerning the enclosed disk is submitted herewith.

10/523,836

JAB-1729USPCT

The USPTO is authorized to charge any necessary fees in connectin with these filings to Deposit Account No. 10-0750 in the name of Johnson & Johnson.

Respectfully submitted,



Ellen Ciambrone Coletti
Reg. No. 34,140
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359



DOCKET NO. JAB-1729 USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Boulanger, D. et al.

Serial No.: 10/523,836

Art Unit: Not yet assigned

Filed : February 7, 2005

Examiner: Not yet assigned

For : **USE OF NF-KAPPA B INHIBITORS FOR THE TREATMENT OF MASTITIS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

11-15-05

(Date of Deposit)

Ellen Ciambone Coletti

(Name of applicant, assignee, or Registered Representative)

[Signature]

(Signature)

11-15-05

(Date of Signature)

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VERIFIED STATEMENT UNDER 37 CFR §1.821(F) and (G)

Dear Sir:

I hereby verify as required by 37 CFR §1.821(f) that the computer readable disk enclosed herewith is identical to the the copy of the printed version of the sequence listing of the subject patent application. I hereby verify that the submission herein as required by 37 CFR §1.821(g), does not contain new matter.

This statement is made with the knowledge that willful false statement and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.


Respectfully submitted,

[Signature]

Ellen Ciambone Coletti
Reg. No. 34,140
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359

PCT



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/523,836	FIRST NAMED APPLICANT Delphine Boulanger	ATTY. DOCKET NO. JAB-1729USPCT
---	---	-----------------------------------

INTERNATIONAL APPLICATION NO. PCT/EP03/50373

I.A. FILING DATE 08/12/2003	PRIORITY DATE 08/14/2002
--------------------------------	-----------------------------

Philip S Johnson
 Johnson & Johnson
 One Johnson & Johnson Plaza
 New Brunswick, NJ 08933-7003

RECEIVED

SEP 19 2005

J&J PAT. DKT. SECTION

CONFIRMATION NO. 2401

371 FORMALITIES LETTER



OC000000017004586

Date Mailed: 09/15/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/523,836	PCT/EP03/50373	JAB-1729USPCT

FORM PCT/DO/EO/922 (371 Formalities Notice)